Chapter 12: Tumor immunology and immunotherapy and inflammation (Book, main) Flashcards

1
Q

I think a lot of these cards are already seen as ‘common knowledge’, but just in case: the following cards will be refresher.

A

Ok

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Immune cells arise from two types of progenitor cells. What two cells?

A

Myeloid and lymphoid progenitor cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Name cells that respond early and non-specifically to infection and are thus part of the innate immune response.

A

Neutrophils, eosinophils, basophils, dendritic cells, natural killer cells and macrophages.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Name cells that respond later during infection and are thus part of the adaptive immune response.

A

B cells and T cells (helpter T cells and cytotoxic T cells).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How can the immune system play a dual role in cancer?

A

It as both anti-tumor as pro-tumor effects.

  • Anti-tumor: immune cells can recognize and eliminate tumor cells.
  • Pro-tumor: antigens of cancer cells that are shaped by the immune system could lead to evasion of the immune system and cancer promotion.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the main function of B cells?

A

To synthesize and secrete antibodies (humoral immunity). Antibodies can recognize almost any antigen encountered by the immune system and can coordinate cell-mediated cell lysis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Antibody production may be triggered by protein, lipid, or polysacchardide antigens and requires B cell-T cell interaction. What is the result of this interaction?

A

B cell differentiation into memory B cells and plasma cells that produce IgG antibodies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How can a single clone of a specific B be grown experimentally in order to produce quantities of a specific monoclonal antibody?

A

By creating hybridoma, a hybrid cell formed by fusing a B cell with a B cell cancer cell (myeloma).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

T cells (CD4+ and CD8+ effector T cells) are responsible for cell-mediated immunity. What does this mean?

A

That they have membrane-bound T cell receptors that can recognize antigens that are presented to them via antigen-presenting cells (APC).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the main target of T cells?

A

Virus-infected cells and tumor cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the function of T regulatory cells?

A

They suppress the function of immune cells and are important regulators of the immune response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

The immune system protects against cancer in three ways. Name these.

A
  1. Protection from viral and bacterial infection that may be caustive agents of cancer.
  2. It helps resolve inflammation, a promotor of cancer.
  3. It can recognize and kill tumor cells.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is immunosurveillance?

A

The concept (hypothesized in mid-20th century) that the immune system recognizes cancer cells as foreign agents and eliminates them.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

The cancer immunity cycle has already been broadly discussed in the lecture. There will be a few cards about this topic in this deck.

A

Ok

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the 7 steps in an immune response against a tumor?

A
  1. Release of cancer cell antigens during tumor cell death.
  2. Cancer antigen presentation on APCs.
  3. Priming and activation of T cells in lymph nodes
  4. Transport to tumors via the bloodstream
  5. Infiltration of T cells into tumors
  6. Recognition of cancer cells
  7. Tumor cell death
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How can antigens be distinguished from self antigens?

A

Tumors have tumor-specific antigens (molecules that are unique to cancer cells) or tumor-associated antigens (molecules that are differentially expressed in cancer and normal cells).

17
Q

Through what molecules on APCs are (tumor) antigens presented so that T cells can recognize the antigen and can get activated?

A

Major histocompatibility complex (MHC) molecules.

18
Q

What is T-cell priming?

A

The events initiating the process of quiescent naive T cells to activated effector T cells.

19
Q

What is one of the most important anti-tumor defenses of the body (that also has memory)?

A

The cytotoxic T-cell response.

20
Q

Describe T cell activation in short

A

APC presents its antigen through MHC to TCR of T cell. CD28 on T cells then binds with its ligand B7 on the APC. This initiates a full T cell response. (There’s also T cell differentiation after T cell activation).

21
Q

What molecules is a competitive inhibitor of B7 and competes with CD28 for binding?

A

CTLA-4, it binds more stronly than CD28 to B7. If CTLA-4 binds, it serves as a negative feedback signal and suppresses T cell function.

22
Q

Describe differences between MHC class I and class II molecules.

A
  • Antigens bound by class I are recognized by CD8+ T cells. Antigens bound by class II are recognized by CD4+ T cells.
  • MHC class I is involved in presentation of intracellular antigens, MHC class II is involved in presentation of extracellular antigens
  • Complex of MHC I + intracellular antigen is transported to the cell surface for antigen presentation. MHC II-extracellular antigen complex are formed in lysosomes and then transported to the cell surface.
23
Q

Programmed death 1 protein (PD-1) and its ligands PD-L1 and PD-L2 are additional co-inhibitory molecules. PD-1 is expressed on T cells. On what cells are its ligands expressed?

A

PD-L2 is expressed on APCs. PD-L1 is expressed on many cell types, including tumor cells, after IFN-y production by effector T cells.

24
Q

What does interaction of PD-L1 on tumor cells and its receptor on activated effector T cells cause?

A

The recruitment of SHP-2 phosphatases and inactivation of the PI3K cascade, blocking the production and secretion of molecules required for a cytotoxic response.

25
Q

What are the three Es in immunoediting?

A

Elimination of cancer, equilibrium (the selection of less immunogenic tumors cells during an anti-tumor response) and escape whereby tumors evade the immune system.

26
Q

What supports the evidence that the immune system can affect the immunogenicity of a tumor?

A

Tumors formed in a deficient immune system are more immunogenic and are hence unedited, whereas tumors formed in immunocompetent hosts are termed edited.

27
Q

Name mechanisms for tumor evasion (don’t learn by heart).

A

Loss of tumor antigens, downregulation of antigen-presenting molecules and tumor resistance to cytotoxic pathway, including overexpression of immune checkpoint protein (e.g. PD-L1).

28
Q

What are immunosuppressive molecules that can be secreted by tumors?

A

TGF-b, IL-10, VEGF and indolamine-2,3-dioxygenase (IDO)

29
Q

Shortly describe the function of the immunosuppressive molcules TGF-b, IL-10, and IDO.

A
  • TGF-b can bind to lymphocytes and alter their phenotype/cytokine secretion profile.
  • IL-10 can prevent dendritic cell maturation and inhibits proliferation and cytokine production of CD4+ T cells.
  • IDO is an enzyme that causes a reduction in the availability of amino acid tryptophan to T cells and inhibits their activation, prolfieration and survival.
30
Q

What do therapeutic antibodies mostly interfere with/cause?

A

They mostly interfere with signal transduction and/or engage with receptors on immune cells that leads to antibody-dependent cellular cytotoxicity or phagocytosis (Fc portion of antibody is important in this).

31
Q

Name types of therapeutic vaccines and shortly describe their function.

A
  • Whole cell vaccines, all antigens that are expressed by a specific tumor are included in the vaccine (e.g. gene-modified tumor cells that express stimulatory molecules for T cells).
  • Peptide-based vaccine, use of tumor-associated antigens or tumor-specific antigens to generate an immune response.
  • Dendritic cell vaccine, reintroduction of isolated dendritic cells cultured and then loaded with specific antigens into the body.
32
Q

What kind of vaccine is Provenge and why?

A

Dendritic cell vaccine, since the vaccine contains a fusion protein that can mature and activate dendritic cells.

33
Q

In the setting of a cancer antigen that is being presented by this APC depicted in the picture. How can be prevented that CTLA-4 will bind to B7 and inhibit T cell activation?

A

Through the use of a human monoclonal antibody against CTLA-4.

34
Q

What is another checkpoint, except CTLA-4, that can be inhibited through the use of monoclonal antibodies?

A

PD-1 on T cell and PD-L1 on tumor cell. (Keep in mind that CTLA-4 prevent total activation of immature T cells while PD-1 blocks T cell activation after they turned into effector T cells).

35
Q

What does the concept of “hot” and “cold” immunogenic tumor environments say about the clinical benefit for patients that are treated with PD-1 and PD-L1 therapies?

A

Patients with PD-L1 negative tumors can also respond to anti-PD-1 or PD-L1 therapy. ((Probably because although these tumors were PD-L1 negative, these tumors are “hot” tumors. –> this is my own reasoning, since the book only tells that hot and cold environments correlate with clinical benefit of PD-1 and PD-L1 therapies but doesn’t tell in what way it correlates)).

36
Q

What is immunotherapy based on tumor-infiltrating lymphocytes (TILs)?

A

This therapy is based on adoptive cell transfer of naturally occuring T cells found in a tumor. These cells have been activated in response to tumor-associated antigens, but, in the body, they are restrained by immunosuppressive molcuels such as CTLA-4. TILs removed from the tumor are also removed from their immunosuppresive environment. This can be used in practice where tumor is cut into small fragments and is cultured to produce pure cultures of lymphocytes. After selecting for anti-tumor activity, they can be expanded ex vivo and transferred back to the patient.

37
Q

Adoptive cell transfer strategies (like TIL immunotherapy) can also involve genetically modifying T cells from the blood, so that they express TCRs that target specific tumor antigens. What T cells are created in this way?

A

Chimeric antigen receptor (CAR) T cells.